Skip to content Skip to sidebar Skip to footer

Healthcare Stocks

Island Pharmaceuticals’ PROTECT clinical trial is delivering the goods!

Investors were evidently pleased with the results out of Island Pharmaceuticals' PROTECT clinical trial...at least if the company's more than doubling in the past two months is anything to go by. The results don't just offer hope to Island's investors, but to people suffering from and vulnerable to Dengue fever, a virus that impacts 400m…

ByNick SundichDecember 5, 2024

Here are 6 ASX CEOs who departed their companies in 2024

Here are 6 ASX CEOs who departed their companies in 2024 Larry Diamond - Zip (ASX:ZIP) Since Afterpay's acquisition, Zip (ASX:ZIP) has been the flagship BNPL company of the ASX. It managed to survive a cash crunch, a spectacular collapse in its valuation as interest rates rose, a merger attempt with Sezzle that ended…

ByNick SundichDecember 5, 2024

Dimerix (ASX:DXB): This exciting Phase 3 biotech could be about to follow in the footsteps of Telix and Neuren

Dimerix (ASX:DXB) is one of the few ASX biotechs in the middle of a Phase 3 trial, and it even has data showing the trial is a success. After years of hard work, the company has advanced its DMX-200 drug into a Phase 3 trial, and it has secured commercial deals worth over A$300m even…

ByNick SundichNovember 27, 2024

These 2 key milestones awaiting Recce Pharmaceuticals could be very exciting and value accretive!

There are 2 key milestones awaiting Recce Pharmaceuticals (ASX:RCE) in the next few months that investors in this company need to look out for. The company has had substantial news flow including clinical trial progress, R&D tax rebates and partnerships for its future clinical endeavours, but only a few have generated significant excitement. Arguably, the most…

ByNick SundichNovember 25, 2024

ESG investing under Trump: As companies scale back ESG initiatives have anti-woke crusaders won, or is there still a future?

Is there a future for ESG investing under Trump? And if so, does it still appear as lucrative? Let's take a look at these questions. Recap of what ESG is Environmental, Social, and Governance (ESG) is a framework used to evaluate a company’s impact on the world beyond its financial performance. ESG criteria help investors assess…

ByNick SundichNovember 21, 2024

The $8.8bn Chemist Warehouse Sigma merger is finally going ahead with the ACCC not killing it off

Nearly a year since the $8.8bn Chemist Warehouse Sigma merger was unveiled, it seems we finally got a definitive answer as to whether or not it will go ahead. The ACCC investigated the deal and there was the risk of it blocking the deal if it reckons it will lessen competition. After all, it raised…

ByNick SundichNovember 11, 2024

Recce’s Phase 2 ABSSSI Clinical Trial is on Track and Producing Outstanding Results

There are encouraging signs from Recce Pharmaceuticals' (ASX:RCE) Phase 2 ABSSSI Clinical Trial (Acute Bacterial Skin and Skin Structure Infections). The trial, is nearing completion, but the results to date have led to a Non-Data Safety Monitoring Board reviewing the trial unanimously recommending it continue. Not only have there been no serious adverse events, but all…

ByNick SundichNovember 6, 2024

Imugene (ASX:IMU): This exciting biotech has multiple clinical trial readouts expected in the next 12 months

Imugene (ASX:IMU) is still valued at over $400m, in spite of being valued at over $2bn back in 2021 and having had a rollercoaster 12 months. Imugene (ASX:IMU) share price chart, log scale (Source: TradingView) Even though it has assets that have passed Phase 2 trials, it has never gotten to Phase 3. Yet it has $93.1m…

ByNick SundichOctober 22, 2024

Island Pharmaceuticals (ASX:ILA): One of the rare ASX biotechs fighting mosquito diseases – and it’s in Phase 2

Island Pharmaceuticals (ASX:ILA) is one of the few (if not the only) ASX-listed Biotechs that is focused on mosquito diseases, primarily Dengue fever. Mosquito diseases, such as Dengue, are expensive to treat and are expected to proliferate due to climate change and the consequential boom in the mosquito population. But maybe Island Pharmaceuticals can help. Introduction…

ByNick SundichOctober 15, 2024

Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!

Investors should expect to see more ASX biotechs focus on Asia in the years ahead. And there are good reasons why. For many companies, the golden market has been the USA, given its population and stringent regulator the Food and Drug Administration (FDA). If a company can commercialise a drug in the USA, it can succeed…

ByNick SundichOctober 15, 2024

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Island Pharmaceuticals’ PROTECT clinical trial is delivering the goods!

Here are 6 ASX CEOs who departed their companies in 2024

Dimerix (ASX:DXB): This exciting Phase 3 biotech could be about to follow in the footsteps of Telix and Neuren

These 2 key milestones awaiting Recce Pharmaceuticals could be very exciting and value accretive!

ESG investing under Trump: As companies scale back ESG initiatives have anti-woke crusaders won, or is there still a future?

The $8.8bn Chemist Warehouse Sigma merger is finally going ahead with the ACCC not killing it off

Recce’s Phase 2 ABSSSI Clinical Trial is on Track and Producing Outstanding Results

Imugene (ASX:IMU): This exciting biotech has multiple clinical trial readouts expected in the next 12 months

Island Pharmaceuticals (ASX:ILA): One of the rare ASX biotechs fighting mosquito diseases – and it’s in Phase 2

Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Add Your Heading Text Here